AZA-Deoxycytidine stimulates proopiomelanocortin gene expression and ACTH secretion in human pituitary ACTH-secreting tumors

Maria Francesca Cassarino, Antonella Sesta, Luca Pagliardini, Marco Losa, Giovanni Lasio, Francesco Cavagnini, Francesca Pecori Giraldi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: It is well known that methylation plays an important role in regulating tissue expression of proopiomelanocortin (POMC) and recent studies have shown that demethylation can occur also in vitro in neuroendocrine tumors. Aim of the present study was to evaluate whether inhibition of methylation modulates POMC expression and ACTH secretion by human corticotrope tumors. Methods: Twenty two ACTH-secreting pituitary tumors were incubated with 5-AZA-2′-deoxycytidine (AZA), an inhibitor of DNA-methyltransferases, with or without 10 nM corticotropin-releasing hormone (CRH). Both dose response (100 nM–10 μM AZA) and time course (4–96 h) experiments were carried out for measurement of ACTH secretion and POMC gene expression. Results: Incubation with AZA increased constitutive POMC expression and ACTH secretion by human corticotrope adenomas. The effect appeared most notable at 24 and 48 h with 1 μM AZA. Incubation with AZA did not exert an additional stimulatory effect on CRH-stimulated POMC and ACTH. Conclusions: The present study shows that AZA increases POMC gene expression and ACTH secretion in human pituitary ACTH-secreting tumors. This can be taken to indicate that mechanisms set into motion by AZA play a role in the regulation of ACTH secretion/POMC expression in tumoral corticotropes and paves the way to further studies in Cushing’s disease.

Original languageEnglish
Pages (from-to)464-469
Number of pages6
JournalPituitary
Volume17
Issue number5
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Pro-Opiomelanocortin
Deoxycytidine
Adrenocorticotropic Hormone
Gene Expression
Neoplasms
Corticotropin-Releasing Hormone
Methylation
Pituitary ACTH Hypersecretion
Neuroendocrine Tumors
Methyltransferases
Pituitary Neoplasms
Adenoma
DNA

Keywords

  • 5-AZA-2′-deoxycytidine
  • ACTH
  • Corticotrope adenoma
  • Cushing’s disease
  • Methylation
  • POMC

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

AZA-Deoxycytidine stimulates proopiomelanocortin gene expression and ACTH secretion in human pituitary ACTH-secreting tumors. / Cassarino, Maria Francesca; Sesta, Antonella; Pagliardini, Luca; Losa, Marco; Lasio, Giovanni; Cavagnini, Francesco; Pecori Giraldi, Francesca.

In: Pituitary, Vol. 17, No. 5, 01.10.2014, p. 464-469.

Research output: Contribution to journalArticle

@article{187ee98efc734c3fa65fcb9bdf2c717f,
title = "AZA-Deoxycytidine stimulates proopiomelanocortin gene expression and ACTH secretion in human pituitary ACTH-secreting tumors",
abstract = "Purpose: It is well known that methylation plays an important role in regulating tissue expression of proopiomelanocortin (POMC) and recent studies have shown that demethylation can occur also in vitro in neuroendocrine tumors. Aim of the present study was to evaluate whether inhibition of methylation modulates POMC expression and ACTH secretion by human corticotrope tumors. Methods: Twenty two ACTH-secreting pituitary tumors were incubated with 5-AZA-2′-deoxycytidine (AZA), an inhibitor of DNA-methyltransferases, with or without 10 nM corticotropin-releasing hormone (CRH). Both dose response (100 nM–10 μM AZA) and time course (4–96 h) experiments were carried out for measurement of ACTH secretion and POMC gene expression. Results: Incubation with AZA increased constitutive POMC expression and ACTH secretion by human corticotrope adenomas. The effect appeared most notable at 24 and 48 h with 1 μM AZA. Incubation with AZA did not exert an additional stimulatory effect on CRH-stimulated POMC and ACTH. Conclusions: The present study shows that AZA increases POMC gene expression and ACTH secretion in human pituitary ACTH-secreting tumors. This can be taken to indicate that mechanisms set into motion by AZA play a role in the regulation of ACTH secretion/POMC expression in tumoral corticotropes and paves the way to further studies in Cushing’s disease.",
keywords = "5-AZA-2′-deoxycytidine, ACTH, Corticotrope adenoma, Cushing’s disease, Methylation, POMC",
author = "Cassarino, {Maria Francesca} and Antonella Sesta and Luca Pagliardini and Marco Losa and Giovanni Lasio and Francesco Cavagnini and {Pecori Giraldi}, Francesca",
year = "2014",
month = "10",
day = "1",
doi = "10.1007/s11102-013-0527-8",
language = "English",
volume = "17",
pages = "464--469",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "5",

}

TY - JOUR

T1 - AZA-Deoxycytidine stimulates proopiomelanocortin gene expression and ACTH secretion in human pituitary ACTH-secreting tumors

AU - Cassarino, Maria Francesca

AU - Sesta, Antonella

AU - Pagliardini, Luca

AU - Losa, Marco

AU - Lasio, Giovanni

AU - Cavagnini, Francesco

AU - Pecori Giraldi, Francesca

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Purpose: It is well known that methylation plays an important role in regulating tissue expression of proopiomelanocortin (POMC) and recent studies have shown that demethylation can occur also in vitro in neuroendocrine tumors. Aim of the present study was to evaluate whether inhibition of methylation modulates POMC expression and ACTH secretion by human corticotrope tumors. Methods: Twenty two ACTH-secreting pituitary tumors were incubated with 5-AZA-2′-deoxycytidine (AZA), an inhibitor of DNA-methyltransferases, with or without 10 nM corticotropin-releasing hormone (CRH). Both dose response (100 nM–10 μM AZA) and time course (4–96 h) experiments were carried out for measurement of ACTH secretion and POMC gene expression. Results: Incubation with AZA increased constitutive POMC expression and ACTH secretion by human corticotrope adenomas. The effect appeared most notable at 24 and 48 h with 1 μM AZA. Incubation with AZA did not exert an additional stimulatory effect on CRH-stimulated POMC and ACTH. Conclusions: The present study shows that AZA increases POMC gene expression and ACTH secretion in human pituitary ACTH-secreting tumors. This can be taken to indicate that mechanisms set into motion by AZA play a role in the regulation of ACTH secretion/POMC expression in tumoral corticotropes and paves the way to further studies in Cushing’s disease.

AB - Purpose: It is well known that methylation plays an important role in regulating tissue expression of proopiomelanocortin (POMC) and recent studies have shown that demethylation can occur also in vitro in neuroendocrine tumors. Aim of the present study was to evaluate whether inhibition of methylation modulates POMC expression and ACTH secretion by human corticotrope tumors. Methods: Twenty two ACTH-secreting pituitary tumors were incubated with 5-AZA-2′-deoxycytidine (AZA), an inhibitor of DNA-methyltransferases, with or without 10 nM corticotropin-releasing hormone (CRH). Both dose response (100 nM–10 μM AZA) and time course (4–96 h) experiments were carried out for measurement of ACTH secretion and POMC gene expression. Results: Incubation with AZA increased constitutive POMC expression and ACTH secretion by human corticotrope adenomas. The effect appeared most notable at 24 and 48 h with 1 μM AZA. Incubation with AZA did not exert an additional stimulatory effect on CRH-stimulated POMC and ACTH. Conclusions: The present study shows that AZA increases POMC gene expression and ACTH secretion in human pituitary ACTH-secreting tumors. This can be taken to indicate that mechanisms set into motion by AZA play a role in the regulation of ACTH secretion/POMC expression in tumoral corticotropes and paves the way to further studies in Cushing’s disease.

KW - 5-AZA-2′-deoxycytidine

KW - ACTH

KW - Corticotrope adenoma

KW - Cushing’s disease

KW - Methylation

KW - POMC

UR - http://www.scopus.com/inward/record.url?scp=84952321299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952321299&partnerID=8YFLogxK

U2 - 10.1007/s11102-013-0527-8

DO - 10.1007/s11102-013-0527-8

M3 - Article

VL - 17

SP - 464

EP - 469

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 5

ER -